| Name: | Dapagliflozin Hydroxy impurity |
| Catalogue No. | VL1650007 |
| CAS No. | 1204222-85-4 |
| Molecular Formula | C21H25ClO7 |
| Molecular Weight | 424.87 |
| Status | In-stock |
| IUPAC Name | (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-ethoxyphenyl)(hydroxy)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| Appearance | White Powder |
| Description | Dapagliflozin Hydroxy impurity (CAS No.: 1204222-85-4) or (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-ethoxyphenyl)(hydroxy)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is a synthetic metabolite of Dapagliflozin which is a selective sodium-glucose cotransporter-2 blocker which diminishes renal glucose reabsorption in an insulin-independent manner and helps in the correction of hyperglycemia and prevention of glucotoxicity. |
| References | KARUMANCHI, KISHORE, et al. “Synthesis of Metabolites of Dapagliflozin: An SGLT2 Inhibitor.” Journal of Chemical Sciences, vol. 132, no. 1, Feb. 2020,https://doi.org/10.1007/s12039-020-1747-x.Bailey, Clifford J., et al. “Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Metformin: A Randomised, Double-Blind, Placebo-Controlled Trial.” The Lancet, vol. 375, no. 9733, June 2010, pp. 2223–33,https://doi.org/10.1016/s0140-6736(10)60407-2. |
